MX2012003007A - Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer. - Google Patents

Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.

Info

Publication number
MX2012003007A
MX2012003007A MX2012003007A MX2012003007A MX2012003007A MX 2012003007 A MX2012003007 A MX 2012003007A MX 2012003007 A MX2012003007 A MX 2012003007A MX 2012003007 A MX2012003007 A MX 2012003007A MX 2012003007 A MX2012003007 A MX 2012003007A
Authority
MX
Mexico
Prior art keywords
bcl
family proteins
sulfonamides
inhibitors
cancer
Prior art date
Application number
MX2012003007A
Other languages
English (en)
Inventor
Naeem Yusuff
Karen Miller-Moslin
Bakary-Barry Toure
Michael Scott Visser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2012003007A publication Critical patent/MX2012003007A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención incluye un compuesto novedoso y métodos para el tratamiento de una enfermedad o de un trastorno mediante la antagonización de las proteínas de la familia Bcl-2, en particular los compuestos de la fórmula (I): (ver fórmula (I)) o una sal farmacéuticamente aceptable de los mismos, así como métodos para el tratamiento de una enfermedad, trastorno, o síndrome asociado con la inhibición de Bcl-2, en particular de las enfermedades hiperproliferativas. La presente invención también incluye composiciones farmacéuticas que incluyen os compuestos de la fórmula (I) y las sales farmacéuticamente aceptables de los mismos.
MX2012003007A 2009-09-10 2010-09-08 Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer. MX2012003007A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24125109P 2009-09-10 2009-09-10
PCT/EP2010/063169 WO2011029842A1 (en) 2009-09-10 2010-09-08 Sulfonamides as inhibitors of bcl-2 family proteins for the treatment of cancer

Publications (1)

Publication Number Publication Date
MX2012003007A true MX2012003007A (es) 2012-04-11

Family

ID=43016684

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012003007A MX2012003007A (es) 2009-09-10 2010-09-08 Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.

Country Status (12)

Country Link
US (1) US8809352B2 (es)
EP (1) EP2475661B1 (es)
JP (1) JP2013504536A (es)
KR (1) KR20120078715A (es)
CN (1) CN102498111A (es)
AU (1) AU2010294292B2 (es)
BR (1) BR112012005343A2 (es)
CA (1) CA2772989A1 (es)
EA (1) EA020586B1 (es)
ES (1) ES2443845T3 (es)
MX (1) MX2012003007A (es)
WO (1) WO2011029842A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2668180B1 (en) * 2011-01-25 2018-08-01 The Regents of The University of Michigan Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
MX2014007730A (es) 2011-12-23 2015-01-12 Novartis Ag Compuestos para inhibir la interaccion de bcl2 con los componentes de enlace.
WO2013096049A1 (en) 2011-12-23 2013-06-27 Novartis Ag Compounds for inhibiting the interaction of bcl2 with binding partners
LT6064B (lt) 2012-10-15 2014-08-25 Vilniaus Universitetas Fluorinti benzensulfonamidai kaip karboanhidrazės inhibitoriai
MD4635C1 (ro) 2013-10-14 2020-01-31 Eisai R&D Management Co., Ltd. Compuşi de chinolină substituiţi selectiv
EP3057948B1 (en) 2013-10-14 2018-03-14 Eisai R&D Management Co., Ltd. Selectively substituted quinoline derivatives
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
US11098021B2 (en) 2015-08-12 2021-08-24 Memorial Sloan-Kettering Cancer Center Phenylsulfonamido-benzofuran derivatives and uses thereof in the treatment of proliferative diseases
MA43871A (fr) * 2016-01-11 2018-11-21 Merrimack Pharmaceuticals Inc Inhibition du lymphome 2 à cellules b (bcl -2) et des protéines apparentées
JP6918829B2 (ja) 2016-01-11 2021-08-11 メリマック ファーマシューティカルズ インコーポレーティッド 血管拡張性失調症及びＲａｄ３関連タンパク質（ＡＴＲ）の阻害
CN117683029A (zh) 2018-04-29 2024-03-12 百济神州有限公司 Bcl-2抑制剂
JP2022522534A (ja) 2019-04-02 2022-04-19 アリゴス セラピューティクス インコーポレイテッド Ｐｒｍｔ５を標的にする化合物
WO2023236814A1 (zh) * 2022-06-10 2023-12-14 成都先导药物开发股份有限公司 一种化合物及其在制备bcl-xl抑制剂中的用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004078163A2 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
WO2003080586A1 (en) * 2002-03-21 2003-10-02 Abbott Laboratories N-sulfonylurea apoptosis promoters
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
ZA200702257B (en) * 2004-08-20 2009-06-24 Univ Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
US8168645B2 (en) 2006-11-15 2012-05-01 Genentech, Inc. Arylsulfonamide compounds
FR2912145B1 (fr) * 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
CN102498111A (zh) 2012-06-13
US20120165298A1 (en) 2012-06-28
WO2011029842A1 (en) 2011-03-17
EA020586B1 (ru) 2014-12-30
JP2013504536A (ja) 2013-02-07
US8809352B2 (en) 2014-08-19
EP2475661A1 (en) 2012-07-18
AU2010294292A1 (en) 2012-03-01
BR112012005343A2 (pt) 2016-03-22
CA2772989A1 (en) 2011-03-17
KR20120078715A (ko) 2012-07-10
EA201200472A1 (ru) 2012-10-30
EP2475661B1 (en) 2013-10-23
AU2010294292B2 (en) 2013-07-18
ES2443845T3 (es) 2014-02-20

Similar Documents

Publication Publication Date Title
MX2012003007A (es) Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer.
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
MX2011009796A (es) Inhibidores de la cinasa pi3.
WO2009155121A3 (en) Inhibitors of pi3 kinase
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
MX2014005928A (es) Inhibidores ciclicos de glutaminasa.
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
PH12021550825A1 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
MX2013011591A (es) Métodos y composiciones para tratar enfermedades neurodegenerativas.
GEP20166484B (en) Protein kinase inhibitors
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
TN2012000248A1 (en) Novel spiropiperidine compounds
MX2013012588A (es) Inhibidores de cinasa.
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
TW200745066A (en) Novel PTP1B inhibitors
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
MX346186B (es) Inhibidores de proteina cinasas.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
EA201190293A1 (ru) Пролекарства триптолида

Legal Events

Date Code Title Description
FG Grant or registration